Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Atrophic Vaginitis" patented technology

Inflammation of the vagina due to thinning of the vaginal wall and decreased lubrication associated with reduced estrogen levels at MENOPAUSE.

Method Of Treating Atrophic Vaginitis

InactiveUS20070264309A1Reducing concomitant liabilityBiocideOrganic active ingredientsGynecologyLong term treatments
This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted vehicle, carrier and / or diluent.
Owner:PEAR TREE WOMENS HEALTH CARE

Method of treating atrophic vaginitis

InactiveUS20090137538A1Reducing concomitant liabilityOrganic active ingredientsBiocideGynecologyLong term treatments
This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted vehicle, carrier and / or diluent.
Owner:KLAMERUS BERNADETTE +1

Method Of Treating Atrophic Vaginitis

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.
Owner:CHOLLET JANET A +2

Estrogen compositions and therapeutic methods of use thereof

A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least one estrogenic compound is present in an amount of about 5 to about 1000 μg estradiol equivalent per unit dose of the composition, and upon application of the composition to the vulvovaginal surface the at least one estrogenic compound is released over a period of about 3 hours to about 30 days. The composition is useful for vulvovaginal administration to treat atrophic vaginitis or a disorder associated therewith, for example in a menopausal or postmenopausal woman. A method for treating a hypoestrogenism-related condition of the urogenital system of a female patient comprises intravaginal administration of at least one estrogenic compound according to a treatment regimen wherein a series of compositions releasing a progressively increasing daily amount of the at least one estrogenic compound is administered over a period of at least about 1 month.
Owner:DRAGTEK CORP

Medicine for treating climacteric syndrome

InactiveCN1509719AMild clinical effectSmall side effectsOrganic active ingredientsSexual disorderIrritationPrasterone
A medicine for treating the woman's climacteric syndrome, especially the senile atrophic vaginitis features that it contains prasterone sodium sulfate. Its advantages are high curative effect, low toxic by-effect, and no irritation to endometrium.
Owner:庞飞 +1

Pharmaceutical composition for treating atrophic vaginitis

The invention discloses a pharmaceutical composition for treating atrophic vaginitis and a preparation method thereof, which aim at solving the problem of treating atrophic vaginitis. The pharmaceutical composition is characterized by being prepared from the following active ingredients: cortex erythrina, smallflower bracketplant herb, tetrapanaxpapyrifer, Tianmu mountain magnolia immature flower, herba taxilli, radix ranunculi ternate, coking malt, scorch-fried medicated leaven, radix ephedrae, spina gleditsiae, peach gum, and cassia twig. Proved by clinical experiments, the drug for treating atrophic vaginitis has the characteristics of good curative effect and higher safety, thus being worth of clinical application and popularization.
Owner:刘晓晖

Compositions for vaginal use

The subject of the invention is compositions for vaginal use containing lupulus (Humulus lupulus) and an excipient base suitable for application in the vaginal and / or vulvar region, for the treatment of vaginal dryness (atrophic vaginitis) and of the disorders correlated thereto, pruritus, burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating the changes in the physiological trophism of the vulvar and vaginal tissue and mucosa.
Owner:POLICHEM SA

Preparation method of powder for treating atrophic vaginitis

The invention discloses a preparation method of powder for treating atrophic vaginitis, aiming at solving the problem in treating atrophic vaginitis. The preparation method is characterized by comprising the following steps of: (1) carrying out reduced pressure distillation on crude powder of himalayan coralbean bark, ternate buttercup root and ephedra root and extracting volatile oil; (2) carrying out reduced pressure boiling on the volatile oil to obtain a filtrate; (3) boiling Trikeraia hookeri, Magnolia amoena, parasitic loranthus, coked malt, coked medicated leaven, spina gleditsiae, peach gum, cassia twig and the medicinal filtrate obtained in the step (1) so as to obtain a filtrate for later use; (4) combining the filtrates in the steps (2) and (3), carrying out reduced pressure concentration so as to obtain a dry extract, and crushing the dry extract to obtain dry extract powder; (5) ejecting the volatile oil obtained in the step (1) into the dry extract powder obtained in the step (4), uniformly mixing, screening in a sieve of 100 meshes and sub-packaging so as to obtain the powder. Clinical trial shows that the powder has the characteristics of being good in effect on treating atrophic vaginitis and high in security, and is worthy of clinical application and popularization.
Owner:QINGDAO CENT HOSPITAL

Treatment with cholinergic agonists

InactiveUS20110195987A1Effectively preventedEffectively treatedBiocideAntimycoticsIntravaginal administrationUpper urinary tract infection
Methods of treating disorders with cholinergic agonists for example, muscarinic receptor agonists such as pilocarpine and cevimeline are provided. In particular, methods of treating and / or preventing interstitial cystitis, yeast infections, urinary tract infections, atrophic vaginitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness by administering a cholinergic agonist to the subject suffering from the disorders are provided. In addition, intra-vaginal administration of cholinergic agonists such as muscarinic receptor agonists to patients suffering from interstitial cystitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness is also provided.
Owner:NAJARIAN THOMAS M D +1

Pharmaceutical compositions with hydrating and lubricating activity

The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and / or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.
Owner:FIDIA FARM SPA

Method of treating atrophic vaginitis

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.
Owner:PEAR TREE WOMENS HEALTH CARE

Method of treating atrophic vaginitis

This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted vehicle, carrier and / or diluent.
Owner:LISHU PHARM CO LTD +1

Heat-clearing and yin-nourishing rice bran oil as well as preparation method and application thereof

The invention belongs to the technical field of medicines and particularly relates to heat-clearing and yin-nourishing rice bran oil as well as a preparation method and application thereof. The heat-clearing and yin-nourishing rice bran oil comprises the following components by weight: 40ml-60ml of rice bran oil, 80mg-120mg of vitamin C, 80mg-120mg of sophocarpidine, 130mg-170mg of a radix saposhnikoviae extract, 180mg-220mg of a lily extract and 80mg-120mg of sodium hyaluronate. The heat-clearing and yin-nourishing rice bran oil is helpful for treating atrophic vaginitis and has the characteristics of high efficiency and low relapse rate.
Owner:ZOUPING JIANYUAN GREASE

Medicinal composition for treating elytritis, preparation and its quality control method

A Chinese medicine in the form of suppository for treating atrophic vaginitis is prepared from 8 Chinese-medicinal materials including epimedium, red peony root, liquorice root, rhubarb, etc. Its preparing process and quality control method are also disclosed.
Owner:LIBOYUAN MEDICINES INST BEIJING

Compositions for vaginal use

The object of the present invention is a vaginal composition comprising hops (Humulus lupulus) and an excipient base, suitable for application in the vaginal and / or vulvar area, for vaginal dryness (atrophic vaginitis) and conditions related thereto, pruritus , burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating changes in the trophic effects of vulvar and vaginal tissues and mucosal physiology.
Owner:POLICHEM SA

Application of traditional Chinese medicinal composition in preparing drugs for preventing and/or treating atrophic vaginitis

The invention relates to the field of traditional Chinese medicines and particularly provides application of a traditional Chinese medicinal composition in preparing drugs for preventing and / or treating atrophic vaginitis. The traditional Chinese medicinal composition provided by the invention is prepared from the following raw materials: rhizoma alismatis, semen plantaginis, herba patriniae, floslonicerae, cortex moutan, herba hedyotidis diffusae, radix paeoniae rubra, agrimonia pilosa, rhizoma coptidis and cortex phellodendri. The traditional Chinese medicinal composition can be used for preparing drugs for preventing and / or treating the atrophic vaginitis and has obvious curative effects. The traditional Chinese medicinal composition has significantly improvement on symptoms of increased pH value of vagina, decrease of estrogen in blood and urine, reduction of microecological diversity, reduction of bacterial gene abundance and the like; the probability that a body is suffered fromthe atrophic vaginitis can be effectively prevented; meanwhile, the treatment effect on the atrophic vaginitis is also obvious, the blank that the atrophic vaginitis especially senile vaginitis cannot be effectively treated is filled up and the abuse of antibiotics is avoided. The components of the traditional Chinese medicinal composition are all Chinese herbal medicines and can be repeatedly used for a long time.
Owner:LONGSHUNRONG PHARMA FACTORY TIANJIN ZHONGXIN PHARMA GRP +1

Dhea bioadhesive controlled release gel

The DHEA bioadhesive controlled release gel includes DHEA mixed in a polymeric gel for the purpose of treating atrophic vaginitis, vaginal dryness, dyspareunia, itching, burning, irritation, increase in pH and decreased vaginal flora. The gel adheres to vaginal tissue and protects the DHEA from systemic absorption, which prevents leakage, loss of DHEA, and elevated levels of systemic DHEA. The gel is configured to slowly erode over time so as to deliver a predetermined dose of DHEA to vaginal tissue and thereby promote local intracellular conversion to estrogens, androgens and progesterone so that normal levels of fluid in the vagina is produced. The gel also acts as a moisturizer. An adjustable applicator may also be provided to insure proper placement and dose of the DHEA.
Owner:DHEA

Application of traditional Chinese medicine composition in preparation of medicine for preventing and/or treating atrophic vaginitis

The invention relates to the field of traditional Chinese medicine, in particular, it provides an application of a traditional Chinese medicine composition in the preparation of medicines for preventing and / or treating atrophic vaginitis. The traditional Chinese medicine composition provided by the present invention, raw materials include: Alisma, plantago, Patrinia, honeysuckle, Moutan cortex, Hedyotis diffusa, Radix Paeoniae Rubra, Agrimony, Coptis Rhizoma and Phellodendron Phellodendri, the Chinese medicine composition can be used to prepare The prevention and / or treatment of atrophic vaginitis has remarkable curative effect. The traditional Chinese medicine composition can significantly improve symptoms such as increased vaginal pH, decreased estrogen in blood and urine, decreased microecological diversity, and decreased bacterial gene abundance, and can effectively prevent the body from suffering from atrophic vaginitis. probability, and at the same time, the treatment effect on atrophic vaginitis is also very significant, which fills the gap of lack of effective treatment means for atrophic vaginitis, especially senile vaginitis, and avoids the abuse of antibiotics. The components of the Chinese medicine composition are all Chinese herbal medicines and can be used repeatedly and for a long time.
Owner:LONGSHUNRONG PHARMA FACTORY TIANJIN ZHONGXIN PHARMA GRP +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products